Exabis Library
Welcome to the e-CCO Library!
P102: α-Defensins(αDef) 1-3 are specific plasmatic markers for Crohn’s disease (CD) at diagnosis and tissue α-Def 5 methylation is a pathogenic mechanism for αDef-5 down regulation in CD.
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P102: A small molecule selective integrin α4β7 inhibitor demonstrates efficacy in a chronic model of Inflammatory Bowel Disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:48 AM
P102: Changes in serum immune protein profiles following vedolizumab therapy in Inflammatory Bowel Disease.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P102: Hypoxia reduces inflammation through the downregulation of NLRP3/mTOR signaling and the activation of autophagy
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P102: Increased abundance of gut microbial virulence genes and pro-inflammatory pathways during Crohn’s disease exacerbations
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P102: Outcomes of coronavirus disease 2019 among patients with inflammatory bowel diseases and the influence of IBD-related medications– A Danish prospective population-based cohort study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P102: Subclinical atherosclerosis assessed by coronary artery calcium score in patients with Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P103 The treatment effect of tonsil-derived mesenchymal stem cells (T-MSCs) via regulating programmed death-1/programmed death ligand-1 (PD-1/PD-L1) in ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P103: Colitis-associated faecal miRNAs are mediators of host-microbiota interactions and key regulators of intestinal permeability and inflammation
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:48 AM
P103: Degradation and formation of type III, IV and V collagen are associated with disease activity, disease severity and disease extension in patients with ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P103: Evaluation of efficacy of new vectors for siRNA CYCLIN D1 and E2F1 delivery in control of cancer progression in inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P103: Identifying CES-1 positive myeloid cells with mass cytometry as a potential therapeutic target for Crohn’s disease
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P103: Minimal Clinically Important Difference (MCID) for the Ulcerative Colitis Patient-Reported Outcomes Signs and Symptoms (UC-PRO/SS) Tool
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P103: Selective M1 macrophage polarisation in Crohn’s disease in comparison to intestinal tuberculosis: a novel observation
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P103: The identification of lesion-specific gene expression in intestinal epithelial cells of ulcerative colitis by comparing colonic organoids from lesion and non-lesion parts of same patients
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P104 Defective metabolism mediates NK cell dysfunction in inflammatory bowel disease (IBD)
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P104: Exploring the transcriptomic miRNA signatures of Egyptian Inflammatory Bowel Disease patients
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:48 AM
P104: Gene expression profiles in inflamed colonic biopsies from newly diagnosed Crohn’s disease and ulcerative colitis patients differ depending on the age at diagnosis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P104: Icariin Attenuates Intestinal Inflammation through Inhibition of the Nuclear Factor-ĸB signaling
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P104: Inflammatory complications of the pouch, and therapetic requirements after colectomy in patients with ulcerative colitis. Results from the RESERVO Study of GETECCU
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM